Regarding the AKI-related hospitalization rate, we observed decreased hospitalization rates in SGLT2 inhibitor users compared with non-users (HR 0.66, 95% CI 0.50–0.88) (Figure 7). This evidence concerns the gene SLC5A2 and acute kidney injury.